Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP8062 Interaction with Buprenorphine/Naloxone in OUD
NCT04447287Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in opioid use disorder (OUD) comparing ASP8062 Arm with Placebo Arm (2 arms). Primary endpoints: Number of Participants With Adverse Events, Number of Participants With Suicidal Ideation and/or Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) and 2 more. Started Jun 2020; status: completed.
02
Drugs
ASP8062
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT04447287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04447287.